

New Benitec website: better investor communications

27 June 2007, Melbourne, Australia: Benitec Limited (ASX: BLT) has today launched its new website as part of the company's initiatives to improve stakeholder and investor communications. Investors and those interested in learning more about medical therapies from gene silencing are encouraged to log on to www.benitec.com.

The emphasis is investor friendly and simple explanations of the world of RNAi-mediated gene silencing and Benitec's IP and commercial position. The website's investor relations section will be continually updated with latest company announcements, quarterly newsletters, stock prices, research reports and financials. Investors are encouraged to register to receive email updates.

Chief Executive Officer, Sue MacLeman commented: "The improved website represents our ongoing dedication to clear and consistent communication with our investors and other stakeholders."

CONTACT:

BENITEC LTD

Sue MacLeman
Chief Executive Officer
+61 437 211 200

Rudi Michelson
Monsoon Communications
+61 411 402 737

About Benitec

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with the Center for Biomedicine & Genetics at the City of Hope in Los Angeles, California, is in Phase I clinical trials. For additional information, please visit www.benitec.com.